Premium
Escitalopram lowers risk of cardiac events in patients with acute coronary syndrome
Publication year - 2018
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30366
Subject(s) - escitalopram , medicine , acute coronary syndrome , placebo , adverse effect , depression (economics) , citalopram , cardiology , myocardial infarction , antidepressant , alternative medicine , macroeconomics , pathology , economics , hippocampus
Use of escitalopram for 24 weeks in patients with depression following acute coronary syndrome (ACS) resulted in a reduced long‐term risk of major adverse cardiac events, a placebo‐controlled study has found. Although the study found no association between escitalopram treatment and mortality outcomes, reduced mortality was associated instead with depressed patients' remission status. Study results were published in the July 24/31 issue of JAMA .